4,876 Shares in Stryker Corporation $SYK Acquired by Ancora Advisors LLC

Key Points

• Ancora Advisors acquired 4,876 Stryker shares worth approximately $1.535 million during the second quarter. Institutional investors collectively own 77.09% of the company.
• Stryker insiders sold 351,267 shares worth about $118.2 million over the past 90 days, including a $100.8 million sale by director Ronda E. Stryker.
• Stryker’s latest quarterly results exceeded expectations, with EPS of $3.69 and revenue of $6.59 billion, while analysts maintain a “Moderate Buy” consensus and an average price target of $386.28.

Ancora Advisors LLC bought a new stake in Stryker Corporation (NYSE:SYK - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 4,876 shares of the medical technology company's stock, valued at approximately $1,535,000.

Several other hedge funds have also bought and sold shares of SYK. Primecap Management Co. CA purchased a new stake in shares of Stryker during the 2nd quarter valued at $213,421,000. Cooper Haims Advisors LLC bought a new position in Stryker in the second quarter valued at $245,000. Canada Pension Plan Investment Board purchased a new stake in Stryker during the second quarter valued at about $153,805,000. Castleark Management LLC purchased a new stake in Stryker during the second quarter valued at about $107,000. Finally, Parkman Healthcare Partners LLC bought a new stake in Stryker during the second quarter worth about $21,401,000. 77.09% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, insider Debra King sold 826 shares of the firm's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares of the company's stock, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 300,000 shares of Stryker stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the sale, the director directly owned 2,301,375 shares in the company, valued at $773,031,862.50. The trade was a 11.53% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is currently owned by corporate insiders.

Stryker Trading Down 2.3%

NYSE SYK opened at $322.20 on Friday. The stock has a market cap of $123.58 billion, a P/E ratio of 33.39, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The stock has a 50 day simple moving average of $328.64 and a two-hundred day simple moving average of $331.47. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm had revenue of $6.59 billion for the quarter, compared to analysts' expectations of $6.58 billion. During the same period in the previous year, the firm earned $3.13 earnings per share. The business's revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker's dividend payout ratio is 36.48%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on SYK. Barclays reduced their price objective on Stryker from $469.00 to $394.00 and set an "overweight" rating on the stock in a research report on Monday, May 4th. JPMorgan Chase & Co. cut their target price on Stryker from $400.00 to $350.00 and set an "overweight" rating for the company in a research note on Friday, July 31st. Weiss Ratings restated a "hold (c)" rating on shares of Stryker in a research report on Friday, July 31st. Argus set a $370.00 price objective on Stryker in a research report on Thursday, July 9th. Finally, Evercore set a $350.00 price objective on Stryker in a research note on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, Stryker has a consensus rating of "Moderate Buy" and a consensus price target of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source